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Abstract During the course of studies to investigate whether MPC circulate in response to G-CSF, the agent most
frequently used to induce mobilization of hematopoietic progenitors, we observed that while G-CSF failed to increase the
number of MPC in circulation (assayed in vitro as fibroblast colony-forming cells, CFU-F), G-CSF administration nevertheless
resulted in a time-dependent increase in the absolute number of CFU-F within the BM, peaking at Day 7. Treatment of BM cells
from G-CSF-treated mice with hydroxyurea did not alter CFU-F numbers, suggesting that the increase in their numbers in
response to G-CSF administration is not due to proliferation of existing CFU-F. Given previous studies demonstrating that G-CSF
potently induces bone turnover in mice, we hypothesized that the increase in CFU-F may be triggered by the bone resorption
that occurs following G-CSF administration. In accord with this hypothesis, administration of an inhibitor of osteoclast
differentiation, osteoprotegerin (OPG), prevented the increase of CFU-F numbers induced by G-CSF. In conclusion, these
data indicate that the cytokine treatment routinely used to mobilize hematopoietic stem cells could provide a readily
applicable method to induce in vivo expansion of MPC for clinical applications.
© 2010 Elsevier B.V. All rights reserved.Introduction to differentiate into all of the cellular elements of the marrowThe bone marrow (BM) contains a rare population of multi-
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as demonstrated by in vitro and in vivo experiments
(Friedenstein et al., 1987; Grigoriadis et al., 1988). The
multilineage differentiation potential of MPCs, their unique
immunosuppressive properties (Tyndall et al., 2007; Uccelli
et al., 2008; Joo et al., 2010) coupled with the relative ease of
their isolation and ex vivo propagation, has engendered
considerable interest in their application in a broad range of
cellular and gene therapies (reviewed in Gronthos and
Simmons, 1996; Fouillard et al., 2007; Bianco et al., 2008;
Porada et al., 2006; Feng et al., 2008; Giordano et al., 2007;
CaplanandDennis, 2006; Berry et al., 2006; Yan et al., 2009). A.
66 N. Brouard et al.notable impediment to the use of MSC in these proposed
clinical applications is the low incidence of MPC in the bone
marrow and the consequent need to aspirate significant
volumes of bone marrow to obtain sufficient starting numbers
to avoid the requirement for ex vivo expansion of MPC and the
attendant risk of senescence or transformation through
excessive proliferation.
Hematopoietic stem/progenitor cells (HSC/HPCs) are also
present at low incidence in bone marrow but their rarity is
partially overcome by the use of various agents which result
in their release into the peripheral circulation, a process
termed stem cell mobilization (for review, see Nervi et al.
(2006)). Among a variety of agents shown to elicit mobiliza-
tion of primitive hematopoietic cells, granulocyte colony-
stimulating factor (G-CSF) is the most frequently used
clinically for stem cell mobilization.
A number of previous reports have described the
generation of colonies of fibroblastic cells following in vitro
culture of normal peripheral blood from a range of adult
mammalian species including humans, mice, rats, rabbits,
guinea pigs, anddogs (Kuznetsov et al., 2001; Fernandez et al.,
1997; Zvaifler et al., 2000; Huss et al., 2000; Rochefort et al.,
2006). In addition, cells with the characteristics of MPC have
also been described in the circulation at early stages of human
development (Campagnoli et al., 2001) and in umbilical cord
blood (Gutierrez-Rodriguez et al., 2000; Erices et al., 2000;
Markov et al., 2007). While not all of the above studies provide
quantitative analysis of CFU-F numbers, the consensus is that
the incidence of MPC in the circulation under steady-state
conditions is extremely low.
In the present study, we sought to investigate whether
MPC can be mobilized in mice in response to administration
of G-CSF. Although we failed to demonstrate increases in the
numbers of circulating CFU-F, administration of G-CSF was
found to elicit a transient increase in the absolute number of
CFU-F within the bone marrow compartment compared to
saline-treated controls. From a series of experiments
designed to investigate the underlying mechanism of this
phenomenon, the transient increase in CFU-F numbers in the
bone marrow was not the result of a direct mitogenic effect
of G-CSF on CFU-F or to proliferation of the marrow resident
pool of MPC. Rather, the data are consistent with a model in
which the increase in CFU-F in the marrow is due to
recruitment of MPCs from a reservoir in the bone tissue as
a consequence of an increase in bone turnover initiated by
G-CSF. In conclusion, these data demonstrate that G-CSF,
a cytokine routinely used to mobilize hematopoietic stem
cells, could also provide a readily applicable method to
induce in vivo expansion of MPC for clinical applications.
Results
Effect of G-CSF administration on the number of
circulating CFU-F
From control and G-CSF-treated mice, we harvested 250 to
500 μl of blood per animal by various methods as described
underMaterials andmethods: intracardiac puncture and retro-
orbital puncture using capillary tubes or 26 G needles.
Following hypotonic hemolysis cells were plated in 24-well
plates in α-MEM 20% FCS, cultured for 10 days, fixed, andstained with toluidine blue. The range of cell number plated
was from 0.1 to 1.2×106, with a mean of 382±60×103 cells for
saline-injectedmice and 400±50×103 for G-CSF-treatedmice.
In four independent experiments (Fig. 1A), we observed the
formation of colonies of monocyte macrophages, typically
between 1 and 3 colonies per blood sample) from the blood of
both control and G-CSF-treated mice (Fig. 1B). These colonies
are readily distinguished from the colonies derived from bone
marrow which comprised stellate or spindle-shaped fibroblas-
tic cells (Fig. 1C). In experimentNo. 2, two blood samples were
collected from each mouse, one from the retro-orbital sinus
using a 26 G needle and the second sample by intracardiac
puncture. None of the testedmice yielded CFU-F colonies from
blood harvested by either route. Analysis of the data
accumulated from four independent experiments demonstrat-
ed that the presence of CFU-F in the peripheral circulation was
observed only rarely with 1 out of 22 mice treated with the
saline vehicle and 3 out of 30 mice treated with G-CSF. In each
of these assays, only 1 to 2 colonies were formed. Based on
these data, we concluded that G-CSF administration does not
induce a significant release of CFU-F into the blood.
G-CSF administration increases the number of
CFU-F in the bone marrow
The failure to mobilize CFU-F into the peripheral circulation
does not preclude the possibility of effects on CFU-F which
remain resident within the bone marrow. To examine this
possibility, bone marrow samples obtained at the same time as
the blood samples from experiment 4 were assayed in parallel
for their content of CFU-F. In contrast to the observations in
blood, G-CSF administration resulted in a statistically signifi-
cant increase inCFU-F numbers in theBMofG-CSF-treatedmice
compared to saline-treatedmice with an approximate doubling
in the incidence of CFU-F in themarrow at Day 7. To determine
the time course of this phenomenon, mice were administered
saline or G-CSF and CFU-F numbers in themarrowwere assayed
at Days 5, 7, 9, and 11. Spleenswere harvested andweighed as a
surrogate measure of the mobilization of hematopoietic stem
and progenitor cells as previously described (Molineux et al.,
1990). As shown in Fig. 2A, at 5 to 11 days of treatment, the
weight of the spleens fromG-CSF-treatedmicewas significantly
increased compared to saline-treated mice by 1.8- to 2.3-fold
(Pb0.001) and accompanying this was a reduction in the
cellular content of the bonemarrow ofmice treatedwith G-CSF
compared to the control group that is statistically significant at
Day 7 (Fig. 2B). In regard to CFU-F numbers, we detected an
increase in CFU-F number in themarrow of G-CSF-treatedmice
compared to saline-treated mice that is maximum and
statistically significant at Day 7 (234±22.9 and 98±8.2 CFU-F
per femur, respectively) and declines to pretreatment steady-
state levels thereafter (Fig. 2C). Thus G-CSF appears to elicit a
transient increase in CFU-F numbers in the bone marrow but
these increases are not reflected in enhanced numbers of these
stromal progenitors in the peripheral blood.
G-CSF does not directly stimulate the proliferation
of MPC in vivo or in vitro
A number of potential mechanisms may be responsible for
the increase in CFU-F numbers in the bone marrow in
Figure 1 Detection of adherent cells in peripheral blood. Mice were treated with saline or G-CSF for 5, 7, 9, or 11 days. The blood
was collected using various methods: * retro-orbital sinus with capillary tube, # retro-orbital sinus with 26G needle, and intracardiac as
described under Materials and methods. Following red blood cells lysis cells were cultured in α-MEM 20% FCS for 10 days, fixed, and
stained with toluidine blue. (A) Number of mice from which at least 1 of the blood sample gave rise to plastic adherent colonies/total
mice tested. Typical colony derived from (B) blood and (C) bone marrow cells.
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are normally in a quiescent state and are not proliferating
(Ben-Ishay et al., 1986). The increase in colony number could
be due to a stimulation of the proliferation of the clonogenic
CFU-F within the bone marrow. To first investigate this, bone
marrow cells from G-CSF or saline-treated mice were treated
with 200 μg/ml hydroxyurea (HU), the agent specifically
cytotoxic to cycling cells under the conditions described
under Materials and methods, washed twice, and plated for
CFU-F assay. As shown in Figure 3, for both G-CSF and saline-
treated mice, the number of colonies formed after treat-
ment was not significantly different from untreated cells.
This suggests that the cells responsible for the formation of
the colony are not cycling at the time they are placed in
culture.
Furthermore some of the authors have shown that in
humans, G-CSF does not directly stimulate the proliferation
of human MPC in a serum-free assay (Gronthos and Simmons,
1995). We used a similar serum-free assay to assess the
effect of G-CSF on mouse MPC proliferation. As shown in
Figure 4, unlike PDGF-AB, EGF or basic-FGF which are well-
established mitogens for MPC (Gronthos and Simmons, 1995;
Doucet et al., 2005), G-CSF did not stimulate the prolifer-
ation of mouse MPC in a serum-free assay. Based on thesedata we conclude that G-CSF does not act by increasing the
proliferation of mouse MPC in the marrow of G-CSF-treated
mice and that the observed increase in CFU-F numbers
following G-CSF administration therefore represent an
indirect effect of the cytokine on mouse stromal progenitor
cells.CFU-F from the marrow of G-CSF-treated mice
exhibit enhanced osteogenic commitment
The bone turnover is the result of a balance between bone
resorption and bone synthesis. Previous studies have shown
that in addition to inducing mobilization of hematopoietic
stem and progenitor cells, G-CSF administration also re-
sults in enhanced bone turnover that is accompanied by
increased numbers of osteoclasts in the bone marrow
(Takamatsu et al., 1998) and the chronic overexpression
of G-CSF in transgenic mice leads to osteoporosis due to an
increase of osteoclast mediated bone resorption (Takahashi
et al., 1996). We therefore hypothesized that the increase in
CFU-F number observed in G-CSF-treated mice might be
causally linked to the bone remodeling response elicited as a
consequence of cytokine administration. To investigate this
Figure 2 Time course of the increase of CFU-F numbers in the bone marrow of mice treated with G-CSF. Mice were treated with
saline or G-CSF for 5, 7, 9, or 11 days. (A) The spleens of the mice were harvested and weighted as an indicator of HSC mobilization. (B)
Bone marrow cells were flushed from the femur and the number of mononucleated cells was counted. (C) Cells (2×106) from the bone
marrow of saline and G-CSF-treated mice were plated in 6-well plates. Cells were cultured in α-MEM 20% FCS for 10 days, fixed, and
stained with toluidine blue. Colonies with a size greater than 1 mm were scored. The average results from 5 independent experiments
are presented.
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marrow of G-CSF-treated mice exhibited altered levels of
osteogenic commitment compared to that of CFU-F in
control mice. Bone marrow cells were harvested from saline
and G-CSF-treated mice and plated to generate CFU-F and
maintained in osteogenic medium for 5 weeks as described
under Materials and methods. Colonies were then fixed and
double-stained to detect both alkaline phosphatase activity
(AP) and mineral deposition using Von Kossa staining (VK).Figure 3 CFU-F-initiating cells are not cycling in the bone
marrow. Bone marrow cells from saline and G-CSF-treated mice
plated without manipulation, or incubated for 30 min at 37 °C in
the presence or absence of 200 μg/ml of hydroxyurea (HU) prior
to plating in α-MEM 20% FCS. After 10 days cells were fixed and
stained with toluidine blue and colonies greater than 1 mm
diameter were scored.Colonies were then scored according to the following
scheme: colonies lacking both AP activity and VK staining
(AP-VK-) were classified as being derived from uncommitted
progenitors, immature osteoprogenitors as AP+colonies
lacking VK staining (AP+VK-), and differentiated osteopro-
genitors as giving rise to colonies demonstrating both AP
activity and mineral deposition (AP+VK+) (Figs. 5A–C). When
colonies falling into each of these three categories wereFigure 4 G-CSF does not induce in vitro CFU-F formation.
Bone marrow cells (5×105 to 4×106) from untreated mice were
plated in 6-well plates in triplicates in SDM supplemented with
PDGF-AB, EGF, bFGF, or G-CSF. After 10 days cells were fixed
and stained with toluidine blue and colonies greater than 1 mm
diameter were scored.
69G-CSF increases mesenchymal precursor cell numbersenumerated, approximately half of the colonies formed from
the bone marrow of saline-treated, control mice fell into the
undifferentiated (AP-VK-) category (Fig. 5D). In marked
contrast, colonies derived from the bone marrow of G-CSF-
treated mice show a marked reduction in the proportion of
undifferentiated colonies. This was observed in mice treated
with G-CSF for 5, 7, and 9 days where undifferentiated
colonies represented only 30, 25, and 27%, respectively, of
total colonies compared to 52% in saline control bone
marrow. Of note, mice receiving G-CSF continuously over
11 days did not demonstrate a significant reduction in the
proportion of undifferentiated colonies.
We have recently reported that the vast majority of bone
marrow stromal precursors are located in the compact bone
compartment (Short et al., 2009). Therefore, these results
prompted us to hypothesize that the osteogenic colony-
forming cells in the G-CSF-treated mouse bone marrow could
be released from the bone due to increased bone resorption
by higher osteoclast activity. We investigated the effect of
G-CSF treatment on the CFU-F content in the compact bone
compartment after 5 and 7 days of treatment with G-CSF.
There were no statistically significant differences in the total
number of CFU-F in the compact bone fraction of the femur
from the mouse treated with G-CSF for 5 or 7 days as
compared with a similar fraction of femur from the saline-
treated mouse (873±164, 1013±301, and 947±154 CFU-F per
femur, respectively (Fig. 6). These results suggest that only aFigure 5 Increased commitment to the bone fate in CFU-F from G-C
11 days. Cells from the bone marrow of saline and G-CSF-treated
methods for 5 weeks. The cells were fixed and stained for alkaline
toluidine blue. Colonies with a size greater than 1 mm were sc
differentiation: AP+VK-, (C) fully committed bone cells: AP+VK+. (D
expressed as colony per 106 cells plated.minor fraction of CFU-F is recruited into bone marrow by G-
CSF.The increase in the marrow CFU-F number by G-CSF
is achieved through osteoclast functions
We then addressed more directly whether the increase in
CFU-F number in the marrow by G-CSF was dependent on
osteoclast activation, using an osteoclast inhibitor: osteo-
protegerin (OPG). The maturation of osteoclast capable of
bone resorption is dependent on a cell-to-cell interaction
between osteoclast precursors and osteoblasts, which is
mediated by RANK (receptor) on osteoclast precursors and
RANKL (RANK ligand) on osteoblasts. OPG is a soluble ligand
for RANKL, and the binding of OPG to RANKL blocks the
RANKL action leading to the maturation of osteoclast (for
review, see Khosla (2001)). Mice were treated with OPG at a
concentration originally used by Simonet et al. (1997) for
2 days prior to and during the G-CSF administration. As
presented in Figures 7B–D, OPG administration alone had no
significant effect on the bone marrow cellularity, blood cell
count, or CFU-F numbers in the marrow. A slight increase in
the spleen weight of the OPG-treated mice (107±0.5 mg)
compared to that of the saline-treated mice (77±3.2 mg)
was statistically significant (Pb0.001), which may reflect
partial transition of hematopoiesis to spleen due to decreaseSF-treated mice. Mice were treated with saline or G-CSF for 5 to
mice were plated in medium as described under Materials and
phosphatase activity, mineral deposition (Von Kossa), and with
ored as (A) undifferentiated: AP-VK-, (B) committed to bone
) The average results from two independent experiments are
Figure 6 Localization of the CFU-F in the mouse femur. Mice
were treated with saline or G-CSF for 5 to 7 days. The bone
marrow and compact bone cells were obtained as described
under Materials and methods. Cells (2×106) from the bone
marrow and compact bone cells (20×103) of saline and G-CSF-
treated mice were plated in triplicates in 6-well plates. Cells
were cultured in α-MEM 20% FCS for 10 days, fixed, and stained
with toluidine blue. Colonies with a size greater than 1 mm were
scored. Average results from three independent experiments are
presented.
70 N. Brouard et al.in the bone marrow space by OPG. The increase in the spleen
weight and blood cell count in the G-CSF-treated miceFigure 7 Osteoprotegerin treatment prevents the increase of the n
were treated with saline for 7 days or G-CSF for 7 days or OPG and G
start of G-CSF administration. (A) The spleens of the mice were harv
marrow cells were flushed from the femur and the number of mon
number of mononucleated cells was counted. (D) Cells (2×106) from t
6-well plates. Cells were cultured in α-MEM 20% FCS for 10 days, fix
than 1 mm were scored. Average results from two independent expcompared to those in the saline-treated mice indicates HSC
mobilization. This increase is not inhibited by the adminis-
tration of OPG (Figs. 7A and C), indicating that the reduction
of osteoclast activity did not inhibit HSC mobilization by G-
CSF. On the other hand, the CFU-F number in the marrow of
mice treated with both OPG and G-CSF is not significantly
different from that of the saline-treated group (135.2±39.7
and 95.2±9.3 CFU-F per femur, respectively, Fig. 7D). These
results suggest that the increase in CFU-F number in the
marrow of the G-CSF-treated mouse is a consequence of
increase in osteoclast activity. Nevertheless, we conclude
that the increase in the CFU-F number in the bone marrow of
G-CSF-treated mice is triggered by the increase in the
osteoclast activity in the bone marrow.Discussion
The growing interest for MPCs as therapeutic tools in
multiple hematological and nonhematological disorders
raised the need to investigate alternative source for these
cells. As for HSC that can be mobilized from the marrow to
the peripheral blood, we investigated the possibility of
releasing MPC in the circulation.Detection of MPCs in the circulation
The origin of MPCs in peripheral blood is poorly documented. It
has recently been established that perivascular cellsumber of CFU-F in the bone marrow of G-CSF-treated mice. Mice
-CSF for 7 days, starting OPG administration 2 days prior to the
ested and weighted as an indicator of HSC mobilization. (B) Bone
onucleated cells was counted. (C) Blood was harvested and the
he bone marrow of saline and G-CSF-treated mice were plated in
ed, and stained with toluidine blue. Colonies with a size greater
eriments are presented.
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2009; Crisan et al., 2008). In support, CFU-Fs are also de-
tected in nonskeletal organs such as dermis (Toma et al., 2001)
and adipose tissue (Wagner et al., 2005; Sakaguchi et al., 2005;
Zuk et al., 2002). The low frequency of CFU-F in peripheral
blood and the blood vessel as a source for CFU-F have therefore
raised a possibility that the low level peripheral blood CFU-F
could be a contaminant generated from blood vessels and
surrounding tissues by needle puncture when blood is
collected.
We have observed that the cells forming adherent cell
colonies from blood samples differed in morphology from
those forming colonies derived from bone marrow samples
(Figs. 1A and B). Adherence to plastic is often used as a crude
method to enrich for MPCs but fibroblasts are not the only
cells with such adherent properties. The analysis of the
cellular composition of the adherent layers from long-term
bone marrow culture showed the presence of endothelial like
cells and macrophages (Dexter, 1979). More recently,
Gutierrez-Rodriguez and colleagues have shown that adher-
ent layers generated with human umbilical cord blood
contain only macrophages but no fibroblasts (Gutierrez-
Rodriguez et al., 2000). In the colonies formed from our
blood samples, we did not detect significant phagocytic
activity assayed using Indian ink (data not shown).
There are conflicting reports related to the detection of
MPC in the peripheral blood of patients receiving G-CSF.
These studies have shown that when peripheral blood cells
are plated directly onto plastic, no CFU-Fs are detected
(Kassis et al., 2006; Lazarus et al., 1997) or at very low
frequency (Lund et al., 2008). Furthermore Kassis et al. show
that only with fibrin microbeads MPC-like cells forming
adherent layers are detected in the peripheral blood of G-
CSF-treated patients. Fibrin may provide an appropriate
substrate for the adhesion of circulating MPC. In our study,
we use conditions that we determined optimal for the growth
of mouse bone marrow MPCs (i.e., selected batch of fetal
calf serum and 5% O2). It is possible that circulating MPC have
different cell culture requirements. Previous studies have
shown that colony formation with bone marrow stromal cells
in vitro could be modulated by the presence of feeder cells
(Kuznetsov and Gehron Robey, 1996), and bone marrow cells
themselves can provide the feeder effect. In this sense, it is
possible that some adherent cells from the peripheral blood
sample might have a suppressive effect. In order to test this
hypothesis we performed CFU-F assay for compact bone cells
in the presence or absence of blood cells. We did not detect a
reduction of the CFU-F numbers in the presence of blood
cells, ruling out this hypothesis (data not shown).Mobilization of MPCs into the circulation
Our study did not show a significant difference in the number
of CFU-F detected between the peripheral blood of mice
treated and untreated with G-CSF, indicating that in contrast
to HSC, G-CSF may not be a suitable stimulus for MPC
mobilization. In a recent report Liu et al. report an increase
in the adherent cell number obtained from culture of periph-
eral blood cells of mice treated with rhuG-CSF (Liu et al.,
2007). Other factors such as irradiation may be more efficient
in mobilizing MPCs. Irradiation was in fact used to test thecapacity of marrow stromal fibroblasts to circulate in a
parabiosis setting (Maloney et al., 1985). However, in this
case, too, circulating CFU-Fs are very rare: less than 1 “donor”
CFU-F detected per femur in the irradiated parabiot partner.
In contrast, it has been shown that rats housed in hypoxic
chambers contain a dramatically high level of CFU-F in the
peripheral blood as compared to those housed under
normoxic conditions (Rochefort et al., 2006). However, we
have noted that no difference is detected in the number of
CFU-F in bone marrow in these experiments.
Circulation of MPC could also be stimulated in a
pathological context. In support, cells with MPC phenotype
are detected at higher frequency in the peripheral blood of
acute burn patients (Mansilla et al., 2006). MPCs migrated to
the injury site. One of the possible mechanisms for it is a
response to inflammation which is also thought to cause
migration of MPCs toward tumors, where they contribute to
the tumor microenvironment (Spaeth et al., 2008).
HSC mobilization is generally observed at Days 4–6 post
G-CSF treatment (Sudo et al., 1997). In recent years several
publications have pointed out the importance of bone as the
HSC niche (Arai et al., 2004; Calvi et al., 2003). Since the bone-
forming osteoblasts can be derived from CFU-Fs, the increase
in themarrowCFU-F number 48 h after themobilization of HSC
(Fig. 2) suggests that this phenomenon reflects a mechanisms
responsible for reconstituting the HSC compartment after HSC
mobilization.Increased number of MPC in the bone marrow as a
consequence of increased bone turnover
While the G-CSF treatment did not induce the mobilization of
CFU-F into the peripheral circulation, we observed
an increase in the CFU-F number in bone marrow following
G-CSF treatment, confirming a previous report (Liu et al.,
2007), which hit maximum after 7 days of treatment (Fig. 2).
Using HU, we have demonstrated that the increase in the
CFU-F number is not caused by a direct effect of G-CSF on
the proliferation of the colony-forming cells. The report that
G-CSF receptor is not detected on osteoblasts (Katayama
et al., 2006) supports our conclusion.
It has been demonstrated that administration of G-CSF
stimulates osteoclast-mediated bone resorption (Takamatsu
et al., 1998; Takahashi et al., 1996). The balance between
bone resorption and bone formation is tightly regulated in
order to maintain bone homeostasis. Elevated osteoclastic
activity therefore results not only in a highbone resorption rate
but also in a high bone synthesis rate. Bone-forming osteoblasts
are one of the progeny of CFU-Fs. The increase in the CFU-F
numbers observed could therefore be related to an increase in
the bone formation in response to the bone resorption induced
by the osteoclast activity. Alternatively, the increase in CFU-F
number is a consequence of the bone resorption by osteoclast.
Our results suggest that both seem to be involved.
First, our in vitro bone nodule formation assay indicated
that the G-CSF treatment resulted in a lower proportion of
colonies composed of undifferentiated mesenchymal cells and
increased proportion of colonies consisting of early osteoblas-
tic cells (Fig. 5), suggesting that an increased number of MPCs
may have activated the osteogenic differentiation pathway or
that the MPC migration into the marrow is already committed
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inhibitor of osteoclastmaturation indicated thatOPG inhibited
the G-CSF-induced increase in the marrow CFU-F number,
while it did not inhibit HSC mobilization as indicated by the
spleen weight and blood cell count increases (Fig. 7). This is in
accord with a previous study with pamidronate, a bispho-
sphanate family of inhibitors for bone resorptive activity of
osteoclasts, in that the G-SCF-induced mobilization of HSC is
not affected (Takamatsu et al., 1998). Interestingly, a recent
report has shown that the stimulation of osteoclasts by RANKL
also induces HSC mobilization via a mechanism distinct from
the mechanism involved in G-CSF-induced HSC mobilization
(Kollet et al., 2006).
Recruitment of MPC to bone marrow by G-CSF is
potentially from the bone
Association of the increase in the marrow CFU-F number with
higher bone turnover prompted us to speculate that the
mobilized MPCs are originated from the bone. We have
demonstrated that compact bone represents a large reser-
voir of MPC (Short et al., 2009). However, we did not detect a
statistically significant reduction in the number of CFU-F in
the compact bone fraction of G-CSF-treated mice. The
increase in the marrow CFU-F number was approximately
130 CFU-F per femur (Fig. 6). Considering the number of
CFU-F measured in the compact bone of saline or G-CSF-
treated mice (873±164, 1013±301, and 947±154 CFU-F per
femur), it is unlikely that we were able to accurately
measure the decrease in MPCs of this degree in the compact
bone compartment. However in support of this hypothesis, it
has been recently shown that the number of endosteal
osteoblasts is significantly reduced in mice treated with
G-CSF for 5 days (Semerad et al., 2005) and that the
morphology of the osteoblasts in G-CSF-treated mice is
modified (Katayama et al., 2006). The average length of
osteoblast projection into bone as well as the thickness of the
osteoblasts at the endosteum is reduced inG-CSF-treatedmice
as compared to PBS/BSA-treated animals. In addition we
observed that the bones from G-CSF-treated mice were more
prone to fracture when flushing the marrow, probably caused
by osteoporosis induced by G-CSF. All these observations
suggest that the increase in osteoclast activity loosens the
structure of the bone at the endosteal region, releasing
osteoblasts and osteoprogenitors in the marrow.
In conclusion, while an efficient and clinically applicable
stimulus to release MPC in the circulation is still to be
identified, we propose that G-CSF administration could be
used to provide a temporary increase in MPC in the bone
marrow. Furthermore the increase of bone commitment of
the MPC obtained in such MPC enriched in bone marrow
would make these cells suitable candidates for applications
such as skeletal defect repair.
Material and methods
Cytokine and chemicals
G-CSF was purchased from Amgen Biologicals, (Australia).
Osteoprotegerin was kindly provided by Amgen, Inc. (Thou-
sand Oaks, CA).Animals
Balb/c mice were housed and handled according to the
Australian Welfare procedure. All methods and animal
procedures were reviewed and approved by the Animal
Ethics Committee.
Cytokine and drug administration to mice
For time-course experiments, 10- to 14-week-old male Balb/
C mice were divided into two groups. The first group of mice
received daily subcutaneous injection of human recombinant
G-CSF at a dose of 250 μg/ kg (body weight)/day for 5, 7, 9,
or 11 days. The second group received saline for 5, 7, 9, or
11 days. For each individual experiment each group contains
3–4 animals. For comparative studies, mice were divided
into 4 groups of 4 animals and received daily subcutaneous
injections of saline, human recombinant G-CSF at a dose of
250 μg/ kg of body weight/day for 7 days, osteoprotegerin
(OPG) at a dose of 10 mg/ kg of body weight/day for 10 days,
OPG, for 10 days, and G-CSF for the last 7 days.
Tissue collection
In the initial experiments, blood was harvested from the
retro-orbital sinus with a capillary tube. In subsequent
studies, blood collection was performed as follows in order
to minimize possible contamination of the blood sample by
cells from the blood vessel or surrounding tissues. Mice were
anesthetized by inhalation of isoflurane (David Bull Labora-
tories, Mulgrave, VIC, Australia), and blood was collected
from the retro-orbital sinus using a syringe equipped with 26
G needles which were prerinsed with sterile 10% EDTA
solution. The mouse abdominal cavity was then opened and a
second sample of blood was harvested with a new syringe and
needle by intracardiac puncture. Red cells were lysed by
adding 10 vol of ammonium chloride hypotonic lysis buffer,
and cells were washed with PBS-2% fetal calf serum (FCS,
Hyclone, Logan, UT, USA), prior to being plated for assay of
CFU-F.
Twelve hours after the last injection mice were culled by
cervical dislocation, the femurs were harvested under sterile
conditions, and the outer surface of the bone was extensively
cleaned of any remaining tissues by scraping with a scalpel
blade. The ends of the femora were cut off with a scalpel
blade and bone marrow cells were obtained by flushing with
PBS–2% FCS. The cells obtained after flushing constitute the
bone marrow fraction. Flushed bones were then cut in small
pieces and incubated with collagenase I (3 mg/ml)
(Worthington Biochemical Co., Freehold, NJ, USA) for
45 min at 37 °C under constant agitation as previously
described (Short et al., 2009). Cells released after incubation
constitute the compact bone fraction.
The spleens of the animals were harvested and weighed as
a surrogate measure of mobilization of hematopoietic stem
and progenitor cells.
Standard CFU-F assay
For assay of CFU-F in peripheral blood samples, all
mononuclear cells derived from 250 μl of blood were plated
73G-CSF increases mesenchymal precursor cell numbersin triplicate in medium comprising alpha-MEM supplemented
with 20% of a lot-selected fetal calf serum (Hyclone, Logan,
UT, USA), 5 mM sodium pyruvate, 1% L-glutamine 2 mM, 1%
penicillin–streptomycin (α-MEM 20%FCS). CFU-F derived
from BM were enumerated by plating cells under identical
conditions in triplicate over the range 5×105 to 4×106 total
bone marrow cells and at 104 to 2×104 cells for cells derived
from compact bone. All cultures were maintained in 10%
CO2, 5% O2, humidified air for 10 days and then colonies were
fixed and stained in 0.01% toluidine blue in 2% formalin.
Colonies larger than 1 mm diameter were scored. CFU-F
numbers were expressed as the number of colonies per femur
for the bone marrow and compact bone cell fractions,
respectively.Serum-free CFU-F assay
From 5×105 to 4×106 total bone marrow cells were plated in
triplicate in 6-well plates in serum-deprived medium (SDM):
IMDM supplemented with 1% BSA, recombinant human
insulin (10 μg/ml), transferrin (100 μg/ml), β-mercap-
toethanol (5 × 10-5 M), low-density lipoprotein (LDL)
(20 μg/ml), and L-glutamine 2 mM. All cultures were
maintained in 10% CO2, 5% O2, humidified air for 10 days.
CFU-F were fixed and stained in 0.01% toluidine blue in 2%
formalin. Colonies larger than 1 mm diameter were scored.
The CFU-F numbers were expressed as number of colonies
per 5×105 cells.Hydroxyurea assay
To determine whether increases in CFU-F numbers occurring
in the bone marrow compartment are due to proliferation
of preexisting stromal progenitors, bone marrow cells from
G-CSF-treated and control mice were treated with hydroxy-
urea. The optimal concentration for HU to kill dividing cells
was determined on passaged bone marrow stromal cells
(MSC). Briefly, bone marrow stromal cells were plated at low
density in α-MEM 20% FCS in 75 cm2 flasks and grown for 36–
48 h to ensure a significant proportion were cycling at the
time of harvest. The adherent cells were harvested by
incubation with trypsin–EDTA, washed, and resuspended in
medium and treated in suspension with HU over a dose range
from 5 μg/ml to 1 mg/ml for 30 min at 37 °C. After washing
twice in medium, cells killed as a consequence of HU
treatment were identified by addition of 7-aminoactinomy-
cin D (7-AAD) at a final concentration of 2.5 μg/ml for 5 min
and flow cytometric analyses performed on a FACscan
(Becton Dickinson). Data analysis was performed using Cell
Quest software. The proportion of MSC killed by drug treat-
ment was maximal at concentrations of HU of 200 μg/ml and
above (data not shown). Based on these data, bone marrow
cells were pooled from 3 G-CSF or saline-treated mice and
incubated with HU at a final concentration of 200 μg/ml in
culture medium for 30 min at 37 °C, washed twice with
medium, and plated in triplicate as described above to assay
the content of CFU-F. As a control for HU treatment, cells
were incubated under identical conditions at 37 °C in the
absence of HU and additional aliquots of cells also plated
without any treatment.In vitro bone nodule formation assay
Cells from the bone marrow of saline and G-CSF-treated mice
were plated in triplicate over a range of cell concentrations in
6-well plates in α-MEM 20%FCS supplemented with 1.8 mM
KH2PO4 (BDH Chemicals Ltd. Poole, Dorset, UK), 100 μM L-
ascorbic acid 2-phosphate (ASC-2P; Novachem, Melbourne,
Australia), 5×10-5 M β-mercaptoethanol, and dexamethasone
sodium phosphate at a final concentration of 10-8 M (DEX;
David Bull Laboratories). Culturesweremaintained in 10%CO2,
5%O2 in humidified air andmediumwas replaced twiceweekly
from Day 7, for 5 weeks. Adherent cells were washed with PBS
and formalin-fixed. Alkaline phosphatase activity (AP) was
detected histochemically by incubation with 0.1 mg/ml of
naphtol ASMX-PO4 (Sigma) and 0.6 mg/ml of Red Violet LB Salt
(Sigma) in 0.1 M Tris-HCl, pH 8.3. Cells were then washed in
distilled water and the mineral deposit was detected by
staining with Von Kossa's reagent (VK) (2.5% silver nitrate in
distilled water). Cells were counterstained with toluidine
blue. Colonies larger than 1 mm diameter were scored
according to the three categories indicated in the text.
Statistical analysis
Significant differences were determined using single factor
ANOVA.
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